{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:18:59Z","timestamp":1791033539886,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1038\/sj.bjc.6603287","type":"journal-article","created":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T20:09:21Z","timestamp":1154462961000},"page":"457-462","source":"Crossref","is-referenced-by-count":19,"title":["A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer"],"prefix":"10.1038","volume":"95","author":[{"given":"R","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Trowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Light","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Riemsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,8,1]]},"reference":[{"key":"BF6603287_CR1","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0022-5347(05)64163-8","volume":"168","author":"W Berry","year":"2002","unstructured":"Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168: 2439\u20132443","journal-title":"J Urol"},{"key":"BF6603287_CR2","doi-asserted-by":"crossref","unstructured":"Cabrespine A, Guy L, Chollet P, Fleury J, Gachon F, Cur\u00e9 H, Mouret-Reynier M, Van Praagh I, Penault-Llorca F, Bay J . Phase II study of paclitaxel carboplatin combination versus mitoxantrone in patients with hormone-refractory prostate cancer [conference abstract: no. 301]. In: 2005 Prostate Cancer Symposium. Alexandria, VA: American Society of Clinical Oncology","DOI":"10.1016\/j.urology.2005.08.046"},{"key":"BF6603287_CR3","unstructured":"Cancer Research UK (2004) CancerStats incidence \u2013 UK [web page on the Internet] London: Cancer Research UK"},{"key":"BF6603287_CR4","unstructured":"Cell Genesys. GVAX\u00ae Prostate Cancer Vaccine vs Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer [web page on the Internet] Bethesda, MD: National Institutes of Health"},{"key":"BF6603287_CR5","unstructured":"Centre for Reviews and Dissemination (2001) Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for those Carrying out or Commissioning reviews [CRD report 4] CRD Reports. York: Centre for Reviews and Dissemination"},{"key":"BF6603287_CR6","doi-asserted-by":"crossref","unstructured":"Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R (2006) A systematic review and economic model of the effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess (in press)","DOI":"10.3310\/hta11020"},{"key":"BF6603287_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629\u2013634","journal-title":"BMJ"},{"key":"BF6603287_CR8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","volume":"339","author":"MA Eisenberger","year":"1998","unstructured":"Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Thompson IM, Bueschen AJ, Lowe BA (1998) Bilateral orchidectomy with or without flutamide for metastatic prostate cancer. New Engl J Med 339: 1036\u20131042","journal-title":"New Engl J Med"},{"key":"BF6603287_CR9","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","volume":"21","author":"DS Ernst","year":"2003","unstructured":"Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W (2003) Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21: 3335\u20133342","journal-title":"J Clin Oncol"},{"key":"BF6603287_CR10","unstructured":"James N . A randomised phase II feasibility study of docetaxel (Taxotere) plus prednisolone vs docetaxel (Taxotere) plus prednisolone plus zoledronic acid (Zometa) vs docetaxel (Taxotere) plus prednisolone-+ zoledronic acid (Zometa) plus strontium-89 in HRPC. [Ongoing trial \u2013 ISRCTN12808747]"},{"key":"BF6603287_CR11","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","volume":"17","author":"PW Kantoff","year":"1999","unstructured":"Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17: 2506\u20132513","journal-title":"J Clin Oncol"},{"key":"BF6603287_CR12","volume-title":"Phase III Randomized Study of Docetaxel and Prednisone with versus without Bevacizumab in Patients with Hormone-Refractory Metastatic Adenocarcinoma of the Prostate","author":"W Kelly","year":"2005","unstructured":"Kelly W (2005) Phase III Randomized Study of Docetaxel and Prednisone with versus without Bevacizumab in Patients with Hormone-Refractory Metastatic Adenocarcinoma of the Prostate [Patient Version] [Web Page on the Internet] Bethesda, Maryland: National Cancer Institute"},{"key":"BF6603287_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.clon.2004.07.009","volume":"16","author":"SR Muthuramalingam","year":"2004","unstructured":"Muthuramalingam SR, Patel K, Protheroe A (2004) Management of patients with hormone refractory prostate cancer. Clin Oncol (Royal College of Radiologists) 16: 505\u2013516","journal-title":"Clin Oncol (Royal College of Radiologists)"},{"key":"BF6603287_CR14","unstructured":"National Institute for Clinical Excellence (2002) Guidance on Cancer Services: Improving Outcomes in Urological Cancers: the Manual. London: NICE"},{"key":"BF6603287_CR15","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1200\/JCO.2005.12.187","volume":"23","author":"S Oudard","year":"2005","unstructured":"Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scott\u00e9 F, Banu A, Coscas Y, Guinet F, Poupon M-F, Andrieu J-M (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23: 3343\u20133351","journal-title":"J Clin Oncol"},{"issue":"3, Suppl 1","key":"BF6603287_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1053\/suro.2002.35052","volume":"20","author":"DP Petrylak","year":"2002","unstructured":"Petrylak DP (2002) Chemotherapy for androgen-independent prostate cancer. Sem Urologic Oncol 20 (3, Suppl 1): 31\u201335","journal-title":"Sem Urologic Oncol"},{"key":"BF6603287_CR17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [SWOG 9916]. New Engl J Med 351: 1513\u20131520","journal-title":"New Engl J Med"},{"key":"BF6603287_CR18","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [TAX 327]. New Engl J Med 351: 1502\u20131512","journal-title":"New Engl J Med"},{"key":"BF6603287_CR19","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","volume":"14","author":"IF Tannock","year":"1996","unstructured":"Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CML, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756\u20131764","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6603287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603287","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:22:38Z","timestamp":1684412558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6603287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["BF6603287"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6603287","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}